Geneva Capital Management LLC Reduces Position in Edwards Lifesciences Co. (NYSE:EW)

Geneva Capital Management LLC decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,230 shares of the medical research company’s stock after selling 1,092 shares during the quarter. Geneva Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,127,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after buying an additional 14,610,123 shares in the last quarter. State Street Corp lifted its stake in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after buying an additional 256,538 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after buying an additional 284,918 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after acquiring an additional 696,965 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $555,939,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,739 shares of company stock valued at $2,799,104 in the last three months. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on EW shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Citigroup lifted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Price Performance

EW stock opened at $71.79 on Friday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $72.36 and a 200 day moving average price of $70.36. The stock has a market cap of $42.34 billion, a PE ratio of 10.30, a P/E/G ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.